Name of oncologist:

.....

Contact number:

.....

After-hours contact number:

.....

My name:

.....

My contact number:

.....

Emergency contact:

.....

Emergency contact number:

.....

Important Information for Health Care Providers

This patient is being treated with Tecentriq, which can cause immune-related adverse reactions that involve the lungs, liver, intestines, hormone glands, and other organs, as well as infusion-related reactions. Early diagnosis and appropriate management are essential to minimise any consequences of immune-related adverse reactions.

For suspected immune-related adverse reactions, ensure adequate evaluation to confirm aetiology or exclude other cause. Based on the severity of the adverse reaction, withhold Tecentriq and administer corticosteroids. Specific guidelines for managing immune-related adverse reactions are provided in the **Summary of Product Characteristics**, available at www.medicines.org.uk/emc, and the Physician Education Materials, available for download via the Medicines Authority of Malta website (http://www.medicinesauthority.gov.mt/rmm).

Please contact the patient's Oncologist (details on the left) for more information.

Assess patients for signs and symptoms of pneumonitis, hepatitis, colitis, endocrinopathies (including hypophysitis, adrenal insufficiency, type 1 diabetes mellitus, hypothyroidism, hyperthyroidism), pancreatitis, and infusion related reactions. Other immune-related adverse reactions reported in patients receiving Tecentriq include: neuropathies (Guillain-Barré syndrome, myasthenic syndrome / Myasthenia Gravis), and meningoencephalitis.

Please consult the Summary of Product Characteristics for Tecentriq available at www.medicines.org.uk/emc or via Roche Medical Information (tel: +44 (0)1707 361010 or email: medinfo.uk@roche.com).

▼ *This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.*

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Reporting forms and information can be found at www.medicinesauthority.gov.mt/adrportal. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554. By reporting side effects you can help provide more information on the safety of this medicine.

This educational material is provided by Roche Products Limited and is mandatory as a condition of the Marketing Authorisation in order to further minimise important selected risks.

Tecentriq® ▼ (atezolizumab)

Patient Alert Card

RXUKATEZ00125c
Date of preparation: August 2017

Roche

IMPORTANT:

Tecentriq can cause serious side effects in many parts of your body that need to be treated right away.

Symptoms may occur at any time during treatment or even after your treatment has ended.

Call your doctor right away if you develop any of these new signs or symptoms listed on this card or if your symptoms should get worse.

Also tell your doctor if you experience any other symptoms not listed on this card.

Do not try to treat your symptoms on your own.

Carry this card with you at all times, especially when you travel, whenever you go to the Accident and Emergency department, or when you see another doctor.

IMPORTANT Reminders for Patients

Tecentriq is a medicine to treat adults with *advanced (metastatic) urothelial carcinoma and non-small cell lung cancer*. Like all medicines, this medicine may cause side effects, although not everybody gets them.

If you develop any signs or symptoms, listed under select important safety information after starting treatment with Tecentriq, or if you notice any signs or symptoms not listed on this card, please contact your doctor **immediately**.

You should not start any other medicines during your treatment without talking to your doctor first.

Getting medical treatment early may stop the problem from becoming more serious.

If you have any further questions about your treatment or on the use of this medicine, please contact your doctor.

SELECT IMPORTANT SAFETY INFORMATION

Serious side effects may include lung problems (pneumonitis), liver problems (hepatitis), intestinal problems (colitis), problems in hormone glands (for example thyroid problems or diabetes), nervous system, and other organs. These events may result in signs or symptoms such as:

- **Lungs:** new or worsening cough, shortness of breath, chest pain.
- **Liver:** yellowing of skin or the whites of eyes, severe nausea or vomiting, bleeding or bruising, dark urine, stomach pain.
- **Intestines:** diarrhoea (watery, loose or soft stools), blood in stools, stomach pain.
- **Hormone glands:** extreme tiredness, weight loss, weight gain, change in mood, hair loss, constipation, dizziness, feeling more hungry or thirsty than usual, need to urinate more often, increased sensitivity to cold or heat.
- **Brain:** neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion, sleepiness.
- **Nerves:** severe muscle weakness and numbness, tingling in your hands and feet.
- **Pancreas:** abdominal pain, nausea, vomiting.
- **Reactions associated with infusion** (during or within 1 day of infusion): fever, chills, shortness of breath, flushing.

Getting medical treatment immediately for these signs and symptoms may stop the problems from becoming serious. Your doctor may decide to give you other medicines to prevent complications and reduce your symptoms, and may withhold the next dose of Tecentriq or stop your treatment.

IMPORTANT:

It is important that you carry this card with you **at all times** whilst you are receiving treatment with this medicine and to keep it with you until at least 5 months after your last dose of treatment.

Please ensure you show this card to **all** Healthcare Professionals (including pharmacists and dentists), to any doctor involved in your treatment, and at any visits to the hospital.